Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Jan Styczynski; Gloria Tridello; Lidia Gil; Per Ljungman; Malgorzata Mikulska; Steffie van der Werf; Nina Simone Knelange; Diana Averbuch; Gerard Socié; Hendrik Veelken; Jean-Hugues Dalle; Mahmoud Aljurf; Alphan Kupesiz; Yves Bertrand; Abdelghani Tbakhi; Boris Afanasyev; Bruno Lioure; Hélène Labussière-Wallet; Xavier Poiré; Johan Maertens; Eefke Petersen; Patrice Chevallier; Noel Milpied; John A. Snowden; Ibrahim Yakoub-Agha; Jan Cornelissen; Nicolaas Schaap; Carlo Dufour; Regis Peffault de Latour; Arjan Lankester; Simone Cesaro

doi:10.2478/ahp-2020-0015

Acta Haematologica Polonica
Vol 51, No 2 (2020) Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Vol 51, No 2 (2020)

ORIGINAL RESEARCH ARTICLE

Published online: 2020-06-01

View PDF Download PDF file

Page views 292

Article views/downloads 319

Get Citation

Connect on Social Media

Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Jan Styczynski¹, Gloria Tridello², Lidia Gil³, Per Ljungman⁴, Malgorzata Mikulska⁵, Steffie van der Werf⁶, Nina Simone Knelange⁶, Diana Averbuch⁷, Gerard Socié⁸, Hendrik Veelken⁹, Jean-Hugues Dalle¹⁰, Mahmoud Aljurf¹¹, Alphan Kupesiz¹², Yves Bertrand¹³, Abdelghani Tbakhi¹⁴, Boris Afanasyev¹⁵, Bruno Lioure¹⁶, Hélène Labussière-Wallet¹⁷, Xavier Poiré¹⁸, Johan Maertens¹⁹, Eefke Petersen²⁰²¹, Patrice Chevallier²², Noel Milpied²³, John A. Snowden²⁴, Ibrahim Yakoub-Agha, Jan Cornelissen²⁵, Nicolaas Schaap²¹, Carlo Dufour²⁶, Regis Peffault de Latour⁸, Arjan Lankester⁹, Simone Cesaro²

DOI: 10.2478/ahp-2020-0015

Acta Haematol Pol 2020;51(2):73-80.

Abstract

Background

In patients with acute leukemia, lymphoma and chronic malignancies, donor and/or recipient Epstein-Barr virus (EBV) seropositive status increases the risk of development of chronic graft-versus-host disease (cGVHD) after allo-hematopoietic cell transplantation (allo-HCT), while it has no influence on other transplant outcomes. No data are available on the impact of EBV serostatus on transplant outcomes in patients with nonmalignant hematological disorders.

Objective

We analyzed the influence of the recipient's (R) and donor's (D) EBV serostatus on transplant outcomes (overall survival (OS); relapse-free survival (RFS); relapse incidence (RI); nonrelapse mortality (NRM); acute graft-versus-host disease (aGVHD); cGVHD) in patients with nonmalignant hematological disorders undergoing allo-HCT.

Patients and Methods

A total of 2,355 allo-HCTs performed between 1997 and 2016 for acquired bone marrow failure or hemoglobinopathies were included in this retrospective Registry megafile Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (IDWP-EBMT) study.

Results

Array

Conclusions

Allo-HCT from EBV-seropositive versus EBV-seronegative donors are at 31% higher risk of cGVHD in patients with nonmalignant hematological disorders undergoing allo-HCT; however this difference is nonsignificant in multivariate analysis.

Keywords: hematopoietic cell transplantgraft-versus-host diseaseEpstein-Barr virusoverall survival

Article available in PDF format

View PDF Download PDF file

Acta Haematologica Polonica

About Via Medica Advertising

Bookstore (Ikamed) TVMed

News